Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (4822)	7/8/1998 3:11:00 PM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

Well, disappointing day. Appearing that AGPH may be establishing a new lower trading range approximately 6-9 points lower as things are settling down. All this great news seems to have cost about 23%. Looks like 30 may be the new barrier, with 28 the first hurdle. Hope the monthly scrip data holds up. Maybe it'll runup close to 30 ahead of earnings. Looking like AGPH may not get back with me on the inlicensing payments. sf

To: Joe E. who wrote (4822)	7/8/1998 10:50:00 PM
From: John F Beule	Read Replies (1) \| Respond to of 6136

Another potential use for Viracept? AIDS drug effective against hepatitis B - study BOSTON, July 8 (Reuters) - Yearlong use of an anti-AIDS drug can help prevent liver damage in people suffering from hepatitis B, according to a study by a team of doctors in Hong Kong, Taiwan and Singapore. The drug is lamivudine, sold under the brand name Epivir by Glaxo Wellcome <GLXO.L>, which paid for the study. Reported in Thursday's New England Journal of Medicine, the study involved 358 volunteers with hepatitis B, a liver disease that affects more than 300 million people worldwide and can lead to cirrhosis, liver cancer and death. Among the volunteers, 142 received 25 milligrams of lamivudine daily, while 143 received a daily dose of 100 mg, and the rest took placebo tablets. When the research team, led by Dr. Ching-Lung Lai of the Queen Mary Hospital in Hong Kong, assessed the amount of liver damage in the volunteers, they found improvement in 56 percent of the patients getting the highest dose, versus 49 percent among people who got 25 mg daily. In contrast, only 25 percent of the placebo recipients got better. Because liver damage declined and the drug appeared to be safe, they said, "longer-term treatment should be evaluated." "The findings ... may have a particularly strong impact in Asia, where 75 percent of the approximately 300 million hepatitis B virus carriers in the world live," said Dr. Masao Omata of the University of Tokyo in an editorial in the Journal. Hepatitis B is often spread by infected body fluids. But in Africa and Asia, where the disease is common, it can also be spread from mother to newborn. 20:55 07-08-98 Copyright 1998 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similiar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All active hyperlinks have been inserted by AOL. BTW: PaineWebber is pounding the table on AGPH, so I think Ms Wangs' upcoming comments are going to show no surprises..